Results 31 to 40 of about 7,252 (163)

Treatment of Nonmotor Symptoms in Parkinson's Disease [PDF]

, 2017
Nonmotor symptoms (NMS) are integral to Parkinson's disease (PD) and the management can often be challenging. In spite of the growing evidence that NMS have a key impact on the quality of life of patients and caregivers, most clinical trials still focus on motor symptoms as primary outcomes.
A. Sauerbier, I. Cova, M. Rosa grilo, R. N. Taddei, L. K. Mischley, K. . R. Chaudhuri   +5 more
openaire   +2 more sources

Temporal patterns of motor and nonmotor symptom emergence in Parkinson’s disease: a cluster analysis

Clinical Parkinsonism & Related Disorders
Background: Parkinson’s disease is a heterogeneous disorder characterized by a broad spectrum of motor and nonmotor symptoms. Recent studies suggest that the order of motor and nonmotor symptom development may indicate different subtypes of Parkinson’s ...
Yoko Sugimura, Toru Baba, Tomoko Totsune, Hideki Oizumi, Takafumi Hasegawa, Kyoko Suzuki, Atsushi Takeda   +6 more
doaj   +1 more source

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease [PDF]

Journal of Movement Disorders, 2020
Objective To investigate the efficacy of levodopa/carbidopa/entacapone (LCE) at bedtime for treating sleep disturbance in patients with Parkinson’s disease (PD) with motor fluctuations.
Kye Won Park, Sungyang Jo, Seung Hyun Lee, Yun Su Hwang, Dagyo Lee, Ho-Sung Ryu, Sun Ju Chung   +6 more
doaj   +1 more source

Video‐based diagnostics supported by artificial intelligence as an opportunity to address the epilepsy diagnostic gap: A narrative review

Epilepsia, EarlyView.
Abstract Despite advancements in epilepsy care, a substantial diagnostic gap persists, particularly in resource‐limited settings. This narrative review explores the potential of video‐based diagnostics augmented by artificial intelligence (AI) to address this gap by enabling earlier and more accessible seizure detection and classification.
Gadi Miron, Robert Terziev, Maximilian Schöls, John McLaren, Tobias Loddenkemper, Jörg Wellmer, Sigrid Mues, Christian Meisel   +7 more
wiley   +1 more source

Epidemiological Signals, Knowledge Gaps, and Practice Considerations From the 2024 Functional Neurological Disorder Society International Meeting: A Conference Report With Narrative Synthesis

Medicine Bulletin, EarlyView.
ABSTRACT The 2024 International Conference on Functional Neurological Disorders brought together clinicians, researchers, advocates, and service‐user representatives to discuss recent developments in functional neurological disorder and related functional disorders.
Yadira Velazquez‐Rodriquez, Jennifer Brown, Katherine Gill   +2 more
wiley   +1 more source

Correlates of polyneuropathy in Parkinson’s disease

Annals of Clinical and Translational Neurology, 2020
Objective Previous studies in Parkinson’s disease (PD) patients have demonstrated a high prevalence of polyneuropathy (PNP) and pronounced alpha‐Synuclein pathology in dermal nerve fibers already at early disease stages.
Eva Kühn, Paulina Averdunk, Sophie Huckemann, Katharina Müller, Anne‐Sophie Biesalski, Florian Hof zum Berge, Jeremias Motte, Anna Lena Fisse, Christiane Schneider‐Gold, Ralf Gold, Kalliopi Pitarokoili, Lars Tönges   +11 more
doaj   +1 more source

Parkinson’s Disease Case Ascertainment in the Sister Study: A Cohort for Environmental Health Research

Journal of Parkinson’s Disease, 2023
Background: Large prospective studies are essential for investigating the environmental causes of Parkinson’s disease (PD), but PD diagnosis via clinical exams is often infeasible in such studies.
Zichun Cao, Shengfang Song, Xuemei Huang, Chenxi Li, Zhehui Luo, Aimee A. D’Aloisio, Lourdes Suarez, Dena G. Hernandez, Andrew B. Singleton, Dale P. Sandler, Honglei Chen   +10 more
doaj   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease. [PDF]

PLoS ONE, 2014
Idiopathic Parkinson's disease (IPD) and LRRK2-associated PD (LRRK2-PD) might be expected to differ clinically since the neuropathological substrate of LRRK2-PD is heterogeneous.
Carles Gaig, Dolores Vilas, Jon Infante, María Sierra, Inés García-Gorostiaga, Mariateresa Buongiorno, Mario Ezquerra, Maria José Martí, Francesc Valldeoriola, Miquel Aguilar, Matilde Calopa, Jorge Hernandez-Vara, Eduardo Tolosa   +12 more
doaj   +1 more source

Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Meher Lad, Mark R. Baker, Nicola Pavese   +8 more
wiley   +1 more source